Vanguard Global Advisers’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273K Buy
45,819
+607
+1% +$2.88K ﹤0.01% 2350
2026
Q2
$200K Hold
45,212
– – ﹤0.01% 2501
2026
Q1
$198K Buy
+45,212
New +$213K ﹤0.01% 2444

Other funds holding CTKB

Vanguard Global Advisers's CTKB Position: Q3 2026 in Review

Vanguard Global Advisers increased its Cytek Biosciences (CTKB) stake by 1.3% in Q3 2026, buying an estimated $2.88K and bringing the position to 45,819 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2350.

Vanguard Global Advisers first reported a position in CTKB in Q1 2026 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Vanguard Global Advisers held 45,819 shares of Cytek Biosciences worth $273K as of Q3 2026.
  • Vanguard Global Advisers bought 607 Cytek Biosciences shares in Q3 2026, an estimated $2.88K.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2350 holding.
  • Vanguard Global Advisers first reported a position in Cytek Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.